All analyses
AI analysis

Sunshine Holdings PLC: research report

Fairly valuedneutralNov 17, 2026

Evidence is balanced: September revenue grew 32.0%, while the shares sit near their most expensive year-end valuation record. The catch is that gross margin was the weakest September result on record.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why balanced

  • September-quarter revenue rose 32.0% year-on-year and group net profit grew 76.6%, showing a sharp acceleration in reported earnings.
  • The reported first half delivered 24.4% revenue growth and 44.3% PAT growth, led by healthcare and consumer operations.

Against this. At 2.94 times book value, the shares are more expensive than 90% of diversified-holdings peers.

Operating margin
16.8%sector 9.7%
from 17.4% a year earlier
Net margin
10.8%sector 3.0%
from 8.1% a year earlier, revenue +32.0%
Return on equity
17.0%
twelve months to Sep 30, 2026, unaudited
P/E
17.3sector 14.2
earnings Rs 1.76 per share, year to Sep 2026
P/B
2.94sector 1.20
book Rs 10.38 per share
Dividend yield
5.57%sector 2.08%
96.6% of earnings paid out

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Nov 17, 2026. Sector figures are the median of 22 listed companies in the same sector.

Overview

Sunshine Holdings combines healthcare distribution and manufacturing, consumer brands and agribusiness. The September quarter showed faster sales and profit growth, while the group is also extending healthcare through a Zydus manufacturing venture and a minority stake in Doc990.

The central tension is that the latest operating momentum is strong, but it arrives at a valuation close to the upper end of Sunshine's own record and after a relatively weak gross-margin performance for a September quarter.

Price performance

SUN closed at LKR 30.50 on 17 November 2026. It rose 8.9% over one month, narrowly ahead of the ASPI's 8.2% gain, but fell 18.0% over one year against a 7.7% ASPI decline. The recent rebound therefore has not repaired the longer-period relative shortfall.

The share sits 36.3% up its 52-week range from the low, still 17.5% below the high. Both recent volatility and trading volume are below Sunshine's own year-to-date norms, indicating a quieter recent trading period rather than an unusually active one.

The three-year record contains two falls of 15% or more, with the deepest at 31.4% and not yet recovered. Median daily turnover was LKR 7.2 million; a LKR 1 million order is about 14% of what trades on a typical day, a noticeable part of a day's trading.

Valuation

At 17.3 times earnings for the twelve months to September 2026, the price represents LKR 17.30 for every LKR 1 of trailing profit, above the sector median of 14.2 times. Its 2.94 times P/B means paying LKR 2.94 for each LKR 1 of net assets, versus a 1.16 times sector median. The premium is partly consistent with the trailing 17.0% return on equity, since a higher return on equity supports a higher price-to-book multiple.

The P/B is higher than 90% of sector peers, and the shares were more expensive than at 13 of the last 14 year-ends on both P/E and P/B measures. A buyer at this price is relying materially on the latest quarter: it supplied 41.9% of trailing EPS, and the P/E would be 19.4 times if that quarter had earned its year-ago net margin on the same revenue.

The 5.6% dividend yield is high relative to the sector, but the trailing payout consumed 96.6% of EPS and dividend cover was only 1.04 times. DPS rose to LKR 1.80 in FY2026 from LKR 0.98 in FY2025; FY2027 has LKR 0.50 recorded so far and remains incomplete.

News and sentiment

Company coverage was about normal for Sunshine, with 17 material articles over 90 days: 11 positive, three negative and three neutral. The main reported developments were first-half revenue growth of 24.4%, the Zydus joint venture for a pharmaceutical plant costing more than USD 20 million, and Sunshine Healthcare's LKR 410.8 million acquisition of a 21.92% Doc990 stake.

The Zydus project broadens local pharmaceutical manufacturing, but the disclosures do not quantify its eventual sales or profit contribution. The Doc990 outlay is small beside the group's LKR 73.8 billion trailing revenue, so its immediate earnings effect is unlikely to be decisive on the available information. The LKR 0.50 first interim dividend went ex on 10 November 2026, so a buyer today does not receive it; payment is due on 30 November 2026.

Financials

September-quarter revenue reached LKR 21.6 billion, up 32.0% year-on-year. Operating profit increased 27.5% to LKR 3.6 billion, while group net profit rose 76.6% to LKR 2.3 billion. Sales grew faster than operating profit, so the profit acceleration was not driven by a stronger operating margin.

Gross margin was 29.1% versus 32.1% a year earlier, operating margin was 16.8% versus 17.4%, and net margin was 10.8% versus 8.1%. The gross margin was the worst of seven comparable September quarters. September has been Sunshine's strongest quarter for operating margin on average over six complete years, yet the latest operating margin ranked among its worst September readings, at sixth of seven.

LKR 1.3 billion was absorbed below operating profit by finance costs, tax, associates and other non-operating items. Minority shareholders received LKR 880 million of September group profit, so group net profit is not all attributable to the ordinary shares being valued. Total equity increased to LKR 28.6 billion from LKR 27.3 billion a year earlier, while shares outstanding remained at about 2.0 billion.

Risks

The principal balance-sheet risk is the debt burden relative to equity attributable to owners. At March 2026, debt was LKR 9.5 billion and gearing was 47.8%; this is meaningful leverage, although operating profit covered interest 12.94 times, leaving substantial headroom on the filed annual figures.

The current ratio was 1.73 times, meaning the group had LKR 1.73 of short-term assets, including inventories and customer receivables, for each LKR 1 of bills due within a year. Cash conversion was 0.84 times, so not all operating profit arrived as operating cash in FY2026. Minority interests accounted for 39.4% of FY2026 profit, which makes the earnings available to SUN shareholders materially smaller than the group result alone suggests.

Healthcare represented 57% of reported segment revenue, and reported first-half margins were affected by regulated pharmaceutical price cuts and rupee weakness. These exposures matter most because healthcare is the largest business rather than the whole group.

Outlook

As at 17 November 2026, the next scheduled catalyst is the interim filing for the quarter ending 31 December 2026, expected between 6 and 14 February 2027. It will show whether the September sales acceleration and weaker gross margin continued, and whether the larger healthcare and consumer businesses translated sales growth into operating profit.

The available data cannot quantify the future contribution from the Zydus plant or the Doc990 associate stake. The Zydus facility is reported to target commercial operations in 2028, making near-term reported earnings still primarily dependent on the existing healthcare, consumer and agribusiness portfolio.

About this report. Generated on Nov 17, 2026 from market data up to Nov 17, 2026, 17 material news articles over 90 days and financials to Sep 30, 2026, and scored 55 of 100 on value (fairly valued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports